基于粪菌移植改善糖尿病血管病变的作用机制及临床研究

注册号:

Registration number:

ChiCTR2300077766 

最近更新日期:

Date of Last Refreshed on:

2024-06-19 09:27:20 

注册时间:

Date of Registration:

2023-11-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于粪菌移植改善糖尿病血管病变的作用机制及临床研究

Public title:

Mechanism and Clinical Study on the Amelioration of Diabetic Vasculopathy Based on Fecal Microbiota Transplantation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于粪菌移植改善糖尿病血管病变的作用机制及临床研究

Scientific title:

Mechanism and Clinical Study on the Amelioration of Diabetic Vasculopathy Based on Fecal Microbiota Transplantation

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李珂 

研究负责人:

李珂 

Applicant:

Ke Li 

Study leader:

Ke Li 

申请注册联系人电话:

Applicant telephone:

+86 134 6951 1198

研究负责人电话:

Study leader's
telephone:

+86 134 6951 1198

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

350944254@qq.com

研究负责人电子邮件:

Study leader's E-mail:

350944254@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

宁夏银川市金凤区正源北街301号

研究负责人通讯地址:

宁夏银川市金凤区正源北街301号

Applicant address:

301 Zhengyuan Street North, Jinfeng District, Yinchuan, Ningxia, China

Study leader's address:

301 Zhengyuan Street North, Jinfeng District, Yinchuan, Ningxia, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院)

Applicant's institution:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

研究负责人所在单位:

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院)

Affiliation of the Leader:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

伦审[2023]-NZR-018

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

宁夏回族自治区人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of People's Hospital of Ningxia Hui Autonomous Region

伦理委员会批准日期:

Date of approved by ethic committee:

2023-11-06 00:00:00

伦理委员会联系人:

魏景坤

Contact Name of the ethic committee:

Jingkun Wei

伦理委员会联系地址:

宁夏银川市金凤区正源北街301号

Contact Address of the ethic committee:

301 Zhengyuan Street North, Jinfeng District, Yinchuan, Ningxia, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 951 592 0152

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院)

Primary sponsor:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

研究实施负责(组长)单位地址:

宁夏银川市金凤区正源北街301号

Primary sponsor's address:

301 Zhengyuan Street North, Jinfeng District, Yinchuan, Ningxia, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

宁夏

市(区县):

银川市

Country:

China

Province:

Ningxia

City:

Yinchuan

单位(医院):

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院)

具体地址:

宁夏银川市金凤区正源北街301号

Institution
hospital:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

Address:

301 Zhengyuan Street North, Jinfeng District, Yinchuan, Ningxia, China

经费或物资来源:

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院)

Source(s) of funding:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

研究疾病:

糖尿病周围血管病变  

Target disease:

Diabetic Vasculopathy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价粪菌移植治疗糖尿病血管病变的疗效及安全性,并探讨其可能的机制。  

Objectives of Study:

To assess the therapeutic effectiveness and safety of fecal microbiota transplantation in the treatment of diabetic vasculopathy, and probe into the possible mechanism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.糖尿病急性并发症如糖尿病酮症酸中毒、高渗高血糖综合征、视网膜病变及肾脏病变的患者; 2.入组前2个月内,有连续3天以上抗生素使用史; 3.各种风湿免疫性疾病所致的血管病变的患者;患有严重心脑血管疾病或肝、肾、血液系统及恶性肿瘤疾病; 4.各种感染、近期手术、重度营养不良及其他应激状态的患者; 5.移植通道梗阻:曾接受过胃切除、胃底折叠、结肠造口或其他消化系统手术;以及持续呕吐或怀疑肠梗阻; 6.怀孕; 7.有任何临床上显著或不确定的心理或精神疾病或癫痫; 8.严重免疫系统紊乱。

Exclusion criteria:

1. Patients with acute complications of diabetes, such as diabetes ketoacidosis, hypertonic hyperglycemic syndrome, retinopathy and nephropathy; 2. History of antibiotic use for at least 3 consecutive days within 2 months prior to enrolment; 3. Patients with vascular lesions caused by various rheumatic and immune diseases; Suffering from severe cardiovascular and cerebrovascular diseases or liver, kidney, blood system, and malignant tumor diseases; 4. Patients with various infections, recent surgeries, severe malnutrition, and other stress states; 5. Transplantation channel obstruction, such as gastric resection, fundoplication, colostomy, or other digestive system surgeries; and persistent vomiting or suspected intestinal obstruction; 6. Pregnancy; 7. Have any clinically significant or unspecified psychological or psychiatric illness or epilepsy; 8. Severe immune derangements.

研究实施时间:

Study execute time:

From 2023-11-06 00:00:00 To 2025-11-06 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-11-20 00:00:00 To 2025-11-06 00:00:00

干预措施:

Interventions:

组别:

粪菌移植干预组

样本量:

30

Group:

Fecal Microbiota Transplantation Intervention Group

Sample size:

干预措施:

粪菌移植

干预措施代码:

Intervention:

Fecal Microbiota Transplantation

Intervention code:

组别:

对照组

样本量:

30

Group:

control group

Sample size:

干预措施:

等量生理盐水

干预措施代码:

Intervention:

same volume of saline

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

宁夏 

市(区县):

银川 

Country:

China

Province:

Ningxia

City:

Yinchuan

单位(医院):

宁夏回族自治区人民医院(宁夏医科大学附属第三临床医学院) 

单位级别:

三甲 

Institution
hospital:

People's Hospital of Ningxia Hui Autonomous Region (The Third Clinical Medical College of Ningxia Medical University)

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

宁夏 

市(区县):

银川 

Country:

China

Province:

Ningxia

City:

Yinchuan

单位(医院):

宁夏医科大学附属总医院 

单位级别:

三甲 

Institution
hospital:

General Hospital of Ningxia Medical University (the First Clinical Medical College of Ningxia Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

宁夏 

市(区县):

银川 

Country:

China

Province:

Ningxia

City:

Yinchuan

单位(医院):

宁夏医科大学  

单位级别:

大学 

Institution
hospital:

Ningxia Medical University

Level of the institution:

University

测量指标:

Outcomes:

指标中文名:

干预12周与基线相比动脉超声多普勒变化

指标类型:

主要指标

Outcome:

Change from baseline in arterial ultrasound doppler at 12 weeks

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清代谢物

指标类型:

主要指标

Outcome:

Serum metabolites

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道微生物群

指标类型:

主要指标

Outcome:

Gut microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

次要指标

Outcome:

HbA1c

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血脂水平

指标类型:

次要指标

Outcome:

Blood lipid levels

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠道通透性

指标类型:

次要指标

Outcome:

intestinal permeability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清炎症因子

指标类型:

次要指标

Outcome:

Serum inflammatory factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Faeces

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

肠黏膜

组织:

Sample Name:

Intestinal Mucosa

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究人员采用随机数字表进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers will use the table of random numbers to make random groups.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

作为发表文章的附件随文章发表而公开。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

As an attachment to the published article, it will be made public with the publication of the article.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-11-20 08:51:54